Key result
Most FACT/GOG-Ntx items show moderate to strong validity for assessing oxaliplatin-induced neuropathy in colorectal cancer.
Why the study?
Oxaliplatin-induced neuropathy is a dose-limiting side effect in colorectal cancer patients that impacts quality of life, necessitating a validated self-reported neuropathy measure.
Observational (n=31)
The FACT/GOG-Ntx scale demonstrates content validity for assessing oxaliplatin-induced neuropathy in colorectal cancer patients.
Supports partial FACT/GOG-Ntx validity for oxaliplatin neuropathy assessment; leaves open full-scale confirmation in colorectal cancer cohorts.
BACKGROUND: Although oxaliplatin is widely established as a standard treatment in colorectal cancer (CRC), oxaliplatin-induced neuropathy has emerged as a prominent dose-limiting side effect associated with quality of life decrements. Ongoing monitoring and management of neuropathy is important for CRC patient quality of life and adherence to treatment. Therefore, a validated self-reported measure of neuropathy would aid in the management and assessment of oxaliplatin-induced neuropathy in clinical practice and research. We sought to evaluate the content validity of the 13-item Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity subscale (FACT/GOG-Ntx) for CRC patients receiving oxaliplatin. AIM: To understand the neuropathy experiences of CRC patients and assess content validity of the FACT/GOG-Ntx. METHODS: Semi-structured concept elicitation and cognitive debriefing interviews were conducted with 31 CRC patients experiencing peripheral neuropathy from current or previous oxaliplatin treatment. Interview data were analyzed using a constant comparative approach, and data were mapped to the FACT/GOG-Ntx to assess content validity. RESULTS: Mean age of the sample was 54 (range 34-82). The sample was primarily Caucasian (84%) and consisted of nearly equal numbers of men and women. Participants described 28 unique neuropathy symptoms; hand tingling (experienced by 87% of respondents); feet tingling (81%); hand numbness (68%); and feet numbness (84%) were most frequently mentioned. Neuropathy symptoms occurring on the feet were most often identified as most bothersome by participants. Eleven of the 13 FACT/GOG-Ntx items exhibited moderate to strong evidence of content validity. Two items related to trouble hearing and ringing in the ears had weak support; however, these items represent severe neuropathy and could be useful for a patient reported outcome measure. CONCLUSION: The FACT/GOG-Ntx represents the key neuropathy experiences of CRC patients treated with oxaliplatin.
No takes yet. Share an insight, caveat, or question.
Kaiser et al. (2020) conducted an observational in Colorectal cancer with oxaliplatin-induced peripheral neuropathy (n=31). Oxaliplatin-induced peripheral neuropathy was evaluated on Content validity of the 13-item FACT/GOG-Ntx subscale. Eleven of the 13 FACT/GOG-Ntx items exhibited moderate to strong evidence of content validity for assessing neuropathy in colorectal cancer patients treated with oxaliplatin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: